Ratings Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Market Closed - Nasdaq Copenhagen 10:59:58 2024-03-01 am EST 5-day change 1st Jan Change
649 DKK -2.26% Intraday chart for Zealand Pharma A/S +35.77% +73.90%

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+73.90% 5.86B
B
+6.36% 112B
B+
+11.91% 106B
B+
+4.60% 23.03B
B
-24.38% 21.96B
A-
-13.83% 21.62B
B+
-6.40% 19.13B
A-
-8.51% 17.22B
B
-0.35% 13.07B
C+
+33.43% 12.06B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW